Armodafinil is the R-enantiomer of modafinil, indicated for excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work sleep disorder. It has a longer half-life than modafinil, potentially providing more sustained wakefulness throughout the day with once-daily dosing.
Clinical Overview
Primary Clinical Applications
Armodafinil is indicated to improve wakefulness in patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome (as adjunctive therapy), and shift work sleep disorder. It may also have off-label use for fatigue in depression, multiple sclerosis, and other conditions.
Mechanism and Clinical Benefits
Armodafinil’s exact mechanism is unknown but likely involves dopamine reuptake inhibition and effects on histamine, norepinephrine, and orexin systems. Unlike traditional stimulants, it promotes wakefulness without significant effects on blood pressure or heart rate and has lower abuse potential.
Clinical Considerations
Armodafinil provides sustained wakefulness for 12-15 hours with once-daily morning dosing. It does not typically interfere with nighttime sleep when taken in the morning. The medication has minimal effects on appetite and does not cause the rebound hypersomnia seen with traditional stimulants.
Key Clinical Points
Reduces hormonal contraceptive efficacy
Armodafinil induces CYP3A4 and can render hormonal contraception less effective. Alternative or additional contraception should be discussed before starting and continued for a period after stopping.
Serious rash including Stevens-Johnson syndrome
Serious dermatologic reactions and multi-organ hypersensitivity have been reported. Any emerging rash warrants immediate discontinuation and evaluation rather than watchful waiting.
Adjunct, not a substitute, in sleep apnoea
In obstructive sleep apnoea armodafinil is indicated only as adjunctive therapy. It treats residual sleepiness and does not address the underlying airway obstruction, so CPAP or equivalent must continue.
Lower abuse potential than stimulants
A Schedule IV agent that promotes wakefulness without meaningful effects on blood pressure or heart rate, and without the rebound hypersomnia seen with traditional stimulants. Still requires monitoring for misuse.
Halve the dose in severe hepatic impairment
Dose should be reduced by 50 percent in severe hepatic impairment, and lower doses considered in older adults because of reduced clearance. Avoid late-day dosing to prevent insomnia.
Prescribing Information
Dosing & Administration
Narcolepsy and Obstructive Sleep Apnea – Adults:
- Recommended dose: 150-250 mg once daily in the morning
- Range: 150-250 mg daily
- Maximum: 250 mg daily
Shift Work Sleep Disorder – Adults:
- Recommended dose: 150 mg once daily
- Timing: Take ~1 hour before start of work shift
- Maximum: 150 mg daily
Hepatic Impairment:
- Severe impairment: Reduce dose by 50%
Elderly:
- Consider lower doses due to potential for decreased clearance
Administration:
- Take with or without food
- Consistent timing each day
- Avoid late-day dosing to prevent insomnia
Indications
- Improve wakefulness in patients with excessive sleepiness associated with narcolepsy
- Adjunctive therapy for excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome
- Improve wakefulness in patients with excessive sleepiness associated with shift work sleep disorder
Contraindications
- Known hypersensitivity to armodafinil, modafinil, or any component
- History of left ventricular hypertrophy or ischemic ECG changes
- History of mitral valve prolapse with CNS stimulants
Warnings & Precautions
- Serious rash: Stevens-Johnson syndrome and other serious skin reactions reported
- Psychiatric symptoms: May exacerbate psychosis, mania, or depression
- Cardiovascular effects: Monitor in patients with cardiovascular disease
- Multi-organ hypersensitivity: Rare but serious reactions
- Persistent sleepiness: Patients should avoid driving if excessively sleepy
- Pregnancy: Hormonal contraceptives may be less effective
Drug Interactions
- CYP3A4 substrates: Armodafinil may induce CYP3A4
- Hormonal contraceptives: Reduced effectiveness, use alternative contraception
- Warfarin: Monitor INR more frequently
- CYP2C19 substrates: May increase levels (omeprazole, phenytoin)
Adverse Reactions
Common (≥5%):
- Headache, nausea, dizziness, insomnia
- Anxiety, dry mouth, diarrhea
Serious:
- Serious rash, multi-organ hypersensitivity, psychiatric symptoms
Special Populations
- Hepatic Impairment: Severe impairment: reduce dose by 50%
- Renal Impairment: Use caution in severe impairment
- Elderly: Consider dose reduction due to decreased clearance
- Pregnancy: Category C – may reduce hormonal contraceptive effectiveness
- Controlled substance: Schedule IV – monitor for abuse potential
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.
